Objectives The neurofilament light chain (NfL) has emerged as a versatile biomarker for
CNS-diseases and is approaching clinical use. The observed changes in NfL levels are …

INTRODUCTION Blood biomarkers have proven useful in Alzheimer's disease (AD)
research. However, little is known about their biological variation (BV), which improves the …

Biological variation (BV) is one of the most important sources contributing to uncertainty in
laboratory examinations and should be taken into account in any interpretation made. There …

Objectives Serum tryptase is a biomarker of mast cell activation. Among others, it is used in
the diagnosis of anaphylaxis where a significant increase during the acute phase supports …

Objectives Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker for
intracerebral diseases and is approved for clinical use in traumatic brain injury. GFAP is also …

BACKGROUND Biological variation (BV) data have many applications for diagnosing and
monitoring disease. The standard statistical approaches for estimating BV are sensitive to …

Background Growth differentiation factor 15 (GDF-15) is an emerging cardiovascular
biomarker, and a fully automated immunoassay has recently become available. The …

Background Glycated hemoglobin (HbA1c) and glycated serum albumin (GSA) are used to
evaluate the mean blood glucose levels. To ensure safe clinical application of HbA1c and …

Objectives Plasma uracil is a new biomarker to assess the activity of dihydropyrimidine
dehydrogenase before cancer treatment with fluoropyrimidine drugs. Knowledge on the …

Background Clozapine (CLO) is an atypical antipsychotic used in management of treatment-
resistant schizophrenia. Adverse drug reactions are caused by both CLO and its primary …